Cancer, Metastatic Breast Cancer
GRTXGalera TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Tilarginine + nab-paclitaxel + alpelisib in Cancer, Metastatic Breast Cancer. The expected timing is based on the latest available company guidance and may change.
1/25- Ongoing enrollment. 8/13/25- Trial readout aligned with cash runway through 2026.
Verification
Confirm timing and program details against the company announcement or filing.